Medical dermatology company Botanix (ASX:BOT) has today announced that it has received Australian approval for a phase 2 acne study.
The Australian approval comes off the back of approval from the US Food and Drug Administration for the US portion of the trial.
The company says first patients are set to be enrolled in June 2018 with the support of seven leading Australian dermatology sites.
Botanix is developing BTX 1503 a treatment for moderate to severe acne which targets multiple pathologies involved in the development of the disease.
Currently the only product approved to treat acne is Accutane, which can also carry significant side effects.
The company says its treatment is a topically applied product that offers localised delivery to only those areas on the skin with the disease.
Shares in Botanix (ASX:BOT) are trading flat at 14 cents.